Dauntless Investment Group LLC Makes New $144,000 Investment in Leap Therapeutics, Inc. (NASDAQ:LPTX)

Dauntless Investment Group LLC acquired a new stake in shares of Leap Therapeutics, Inc. (NASDAQ:LPTX) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 50,000 shares of the company’s stock, valued at approximately $144,000.

A number of other hedge funds also recently made changes to their positions in the stock. HighTower Advisors LLC acquired a new stake in Leap Therapeutics during the third quarter worth about $65,000. Geode Capital Management LLC raised its holdings in Leap Therapeutics by 18.0% in the third quarter. Geode Capital Management LLC now owns 329,291 shares of the company’s stock valued at $847,000 after buying an additional 50,194 shares during the period. Exome Asset Management LLC purchased a new stake in Leap Therapeutics during the third quarter worth approximately $264,000. HB Wealth Management LLC increased its position in shares of Leap Therapeutics by 103.2% in the fourth quarter. HB Wealth Management LLC now owns 51,500 shares of the company’s stock worth $150,000 after acquiring an additional 26,150 shares in the last quarter. Finally, Key Client Fiduciary Advisors LLC raised its stake in shares of Leap Therapeutics by 12.2% in the 4th quarter. Key Client Fiduciary Advisors LLC now owns 361,253 shares of the company’s stock valued at $1,039,000 after acquiring an additional 39,330 shares during the period. Institutional investors and hedge funds own 30.46% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on LPTX shares. Robert W. Baird downgraded Leap Therapeutics from an “outperform” rating to a “neutral” rating and lowered their price target for the company from $9.00 to $1.25 in a report on Wednesday, January 29th. HC Wainwright reissued a “neutral” rating on shares of Leap Therapeutics in a research report on Thursday, March 27th. Finally, Baird R W cut Leap Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, January 29th.

Leap Therapeutics Stock Performance

Shares of NASDAQ LPTX opened at $0.40 on Thursday. Leap Therapeutics, Inc. has a 1 year low of $0.22 and a 1 year high of $4.79. The stock’s 50-day simple moving average is $0.39 and its 200-day simple moving average is $1.86. The firm has a market cap of $16.30 million, a price-to-earnings ratio of -0.20 and a beta of 0.22.

Leap Therapeutics (NASDAQ:LPTX) last posted its quarterly earnings data on Wednesday, March 26th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.02. As a group, research analysts predict that Leap Therapeutics, Inc. will post -1.84 EPS for the current year.

Leap Therapeutics Profile

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.